Neovasc Announces New Appointments in Regulatory and Clinical Leadership
July 13 2021 - 9:05AM
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”)
(Nasdaq, TSX: NVCN) announced today that it has appointed Lisa
Becker as Vice President, Regulatory Affairs, Global Angina
Therapies and Sarah Gallagher as Vice President, Clinical Affairs.
“Neovasc’s Regulatory and Clinical teams will be well
strengthened with the additions of Lisa and Sarah, who bring
tremendous experience in regulatory and clinical affairs to the
overall Neovasc team,” said Fred Colen, President and Chief
Executive Officer of Neovasc. “We look forward to leveraging their
industry expertise as we pursue our own development goals in North
America and Europe.”
Ms. Becker has more than 20 years of experience in medical
device regulatory affairs. Her product and therapy experience has
spanned medical devices from cardiac rhythm management, to vascular
support, pulmonary artery pressure monitoring, cardiac occluders,
heart valves and most recently, structural heart products,
previously working at Abbott, St. Jude Medical, Boston Scientific
and Guidant. She possesses regulatory experience on a global scale,
with responsibility for multiple geographies, including US and EU
Class III approvals. Ms. Becker earned a Bachelor of Science in
Organizational Behavior with a General Engineering minor from the
United States Air Force Academy and a Masters of Science from
Chapman University. She served nearly ten years on active
duty as an officer in the US Air Force. A highlight of Ms. Becker’s
career includes the approval of the world's smallest mechanical
heart valve and a duct occluder for premature infants, which was
approved in four major geographies within a six-month period.
“I view my regulatory work as a continuation of my service
toward improving lives. As a member of the Neovasc team, I will
bring my professional passion for driving medical device
development through creative and collaborative regulatory approval
strategies to the Company’s efforts to expand approval and
acceptance of the Reducer device,” said Ms. Becker.
Ms. Gallagher brings 20 years of medical device clinical
research experience to the Neovasc team. Prior to joining
Neovasc, she held leadership roles at Medtronic in Interventional
Pain, Neuromodulation, and Cardiac Rhythm Management, as well as
St. Jude Medical in Structural Heart. During her tenure she
held roles with increasing responsibility in clinical research and
clinical operations, and she has developed and executed both pre-
and post-market clinical trials and supported regulatory approvals
globally. Ms. Gallagher holds a Bachelor of Applied Arts in
Exercise Science and a Bachelor of Arts in Psychology from the
University of Minnesota, and Master of Science in Technology
Management from the University of St. Thomas.
“I am excited to be joining the Neovasc Clinical Affairs team at
this critical point in the Company’s corporate and clinical
journey,” said Ms. Gallagher. “I am eager to engage in the ongoing
and new studies and data supporting the Reducer and Tiara programs,
as we seek to bring these important treatment options to more
patients.”
Neovasc also announces the departure of Vicki Bebeau, former
Vice President of Clinical and Regulatory affairs who is assisting
with transitioning activities to Sarah and Lisa until August 30,
2021.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When
used herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, the Company’s
regulatory and clinical team being strengthened with the additions
of Ms. Becker and Ms. Gallagher, leveraging the industry experience
of Ms. Becker and Ms. Gallagher to pursue the Company’s development
goals in North America and Europe, Ms. Becker’s plans of bringing
collaborative regulatory approval strategies to the Company’s
efforts to expand approval and acceptance of the Reducer device,
Ms. Gallagher’s plans to engage in ongoing and new studies and data
supporting the Reducer and Tiara programs and seeking to bring
these treatment options to more patients and the growing
cardiovascular marketplace. Forward-looking statements are based on
estimates and assumptions made by the Company in light of its
experience and its perception of historical trends, current
conditions and expected future developments, market and other
conditions as well as other factors that the Company believes are
appropriate in the circumstances. Many factors could cause the
Company's actual results, performance or achievements to differ
materially from those expressed or implied by the forward-looking
statements, including those described in the "Risk Factors" section
of the Company's Annual Information Form and in the Management's
Discussion and Analysis for the three months ended March 30, 2021
(copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
InvestorsMike
CavanaughWestwicke/ICRPhone:
+1.646.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICRPhone:
+1.646.866.4012Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024